It sounds like you want to level an accusation around trial data, but are unable to articulate it accurately, or follow through on committing to it in writing in a manner that could see it addressed.
Is there any danger of letting the trial come to a conclusion before you put Veyonda in the bin based on, shall we repeat again, PHASE 1 interim data.
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-22
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 67034 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 21222 | 2 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable